Assessment of ocrelizumab impact on neurofilament levels in multiple sclerosis patients
Authors
Smaranda Maier
Department of Neurology, Faculty of Medicine, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, Romania
Neurology 1 Clinic, Mures County Emergency Clinical Hospital, Targu Mures, Romania
Adina Huțanu
Department of Laboratory Medicine, Faculty of Medicine, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, Romania
Central Laboratory, Mures County Emergency Clinical Hospital, Targu Mures, Romania
Center for Advanced Medical and Pharmaceutical Research, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, Romania
Laura Bărcuțean
Department of Neurology, Faculty of Medicine, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, Romania
Neurology 1 Clinic, Mures County Emergency Clinical Hospital, Targu Mures, Romania
Emanuela Sărmășan
Neurology 1 Clinic, Mures County Emergency Clinical Hospital, Targu Mures, Romania
Rodica Bălașa
Department of Neurology, Faculty of Medicine, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, Romania
Neurology 1 Clinic, Mures County Emergency Clinical Hospital, Targu Mures, Romania
Language: English
Page range: 245 - 254
Submitted on: Apr 11, 2024
Accepted on: Apr 23, 2024
Published on: Jul 31, 2024
Published by: Romanian Association of Laboratory Medicine
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
Related subjects:
© 2024 Smaranda Maier, Adina Huțanu, Laura Bărcuțean, Emanuela Sărmășan, Rodica Bălașa, published by Romanian Association of Laboratory Medicine
This work is licensed under the Creative Commons Attribution 4.0 License.